EVO101

Phase 1Small molecule

VVirginia Clinical Research, Inc.

EVO101 is one of 35 small molecule programs targeting Hidradenitis Suppurativa. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hidradenitis SuppurativaRecruiting

Hidradenitis SuppurativaPhase 1

Recruiting

Competition

Competitive Landscape

36 competitors in Hidradenitis Suppurativa

#DrugCompanyPhaseTrials

Otezla

Amgen

Approved

2 2

Aldactone

Pfizer

Approved

1 3

Soriatane

GSK

Approved

1 4

Daliresp

AstraZeneca

Approved

—5

Botox

RRevance Therapeutics, Inc.

Approved

1 6

Bimzelx

UCB

Phase 3

5 7

Jakafi

Incyte

Phase 3

4 8

Glucophage

Rhapsido

3 10

Rinvoq

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atopic Dermatitis1 trial

Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis

Completed·EEvommune, Inc.·Phase 2·NCT05579899·119 enrolled

Hidradenitis Suppurativa1 trial

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%

Recruiting·VVirginia Clinical Research, Inc.·Phase 1·NCT06645821·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for EVO101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EVO101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EVO101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Virginia Clinical Research, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: VVirginia Clinical Research, Inc.

EVO101

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atopic Dermatitis1 trial

Hidradenitis Suppurativa1 trial

References

Drug Info

Quick Facts

Related News